secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001737287-24-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others
--------------------------------------------------------------------------------

- Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.
- If Notch out-licenses Released Targets, Allogene receives percentage of upfront/milestone payments up to a cap and low single-digit royalties.
- Allogene made ~$22.7M total equity investments in Notch ($5M seed, $15.9M Series A, $1.8M common) and holds ~23% voting interest.
- Amended Agreement includes anti-dilution protections for Allogene's stake in Notch for certain pre-IPO equity financings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/0001737287-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/allo-20240125.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer